CVE-2018-0687

Description

Cross-site scripting vulnerability in Denbun by NEOJAPAN Inc. (Denbun POP version V3.3P R4.0 and earlier, Denbun IMAP version V3.3I R4.0 and earlier) allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.

Category

6.1
CVSS
Severity: Medium
CVSS 3.0 •
CVSS 2.0 •
EPSS 0.36%
Vendor Advisory denbun.com Vendor Advisory denbun.com
Affected: NEOJAPAN Inc. Denbun by NEOJAPAN Inc. (Denbun POP version V3.3P R4.0 and earlier, Denbun IMAP version V3.3I R4.0 and earlier)
Published at:
Updated at:

References

Link Tags
https://www.denbun.com/en/pop/support/security/181003.html vendor advisory
http://jvn.jp/en/jp/JVN00344155/index.html third party advisory
https://www.denbun.com/en/imap/support/security/181003.html vendor advisory

Frequently Asked Questions

What is the severity of CVE-2018-0687?
CVE-2018-0687 has been scored as a medium severity vulnerability.
How to fix CVE-2018-0687?
To fix CVE-2018-0687, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2018-0687 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2018-0687 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2018-0687?
CVE-2018-0687 affects NEOJAPAN Inc. Denbun by NEOJAPAN Inc. (Denbun POP version V3.3P R4.0 and earlier, Denbun IMAP version V3.3I R4.0 and earlier).
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.